ALK-Abelló has acquired Neffy adrenaline nasal spray rights in Europe and Canada from ARS Pharmaceuticals for $145m. ALK plans to launch Neffy in Europe in 2025 and aims for peak sales of $332.8m.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing